Zobrazeno 1 - 10
of 47
pro vyhledávání: '"35"'
Autor:
John J.V. McMurray, Freek W.A. Verheugt, Steen Elkjær Husted, Philippe Gabriel Steg, Marco Alings, Laine Thomas, Michael G. Hanna, Prem Pais, John H. Alexander, Lars Wallentin, Dan Atar, Christopher B. Granger, Basil S. Lewis, Shinya Goto, Philip E. Aylward, Daniel Wojdyla, Kurt Huber, Renato D. Lopes, H. Pouleur
Publikováno v:
European Heart Journal, 35, 4, pp. 224-32
European Heart Journal, 35, 224-32
European Heart Journal, 35, 224-32
Item does not contain fulltext AIMS: We assessed the effect of concomitant aspirin use on the efficacy and safety of apixaban compared with warfarin in patients with atrial fibrillation (AF). METHODS AND RESULTS: In ARISTOTLE, 18 201 patients were ra
Publikováno v:
Scopus-Elsevier
The effect of antihypertensive treatment with lisinopril (10 to 20 mg) on left ventricular mass and diastolic function was studied in 35 patients with mild to moderate hypertension. At baseline 6 and 12 months after treatment responders to lisinopril
Autor:
Hans-Jürgen Rupprecht, John W. Eikelboom, C Yi, Salim Yusuf, J Pogue, Shamir R. Mehta, Basil S. Lewis, Madhu K. Natarajan
Publikováno v:
European heart journal. 23(2)
AIMS Although hirudin is superior to unfractionated heparin for prevention of death, myocardial infarction, or refractory ischaemia in patients with non-ST-elevation acute coronary syndrome, it is not clear whether hirudin is also of benefit in acute
Autor:
Stefano Lattanzio, G. Davi, Nicole Santoro, A. Ganci, Natale Vazzana, Luca Puccetti, Raoul Saggini, Maurizio Averna, Angelo B. Cefalù, Davide Noto
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Low high‐density lipoprotein ( HDL ) levels are major predictors of cardiovascular ( CV ) events, even in patients on statin treatment with low‐density lipoprotein ( LDL ) at target. In animal models HDL s protect LDL from oxidation an
Autor:
Małgorzata Ostrowska, Eliano Pio Navarese, Danuta Rość, Jolanta M. Siller-Matula, Katarzyna Stankowska, Michał Piotr Marszałł, Bernd Jilma, Jacek Kubica, Joanna Sikora, Marek Koziński, Katarzyna Buszko, Piotr Adamski, Wiktor Dariusz Sroka, Julia Maria Kubica
Publikováno v:
European Heart Journal. 37:245-252
Aims The currently available data indicate a drug–drug interaction between morphine and oral P2Y12 receptor inhibitors, when administered together. The aim of this trial was to assess the influence of infused morphine on pharmacokinetics and pharma
Autor:
Volkhard Kurowski, Runlin Gao, Laura Mauri, Farqad Alamgir, Keyur Parikh, Erik Lipsic, Eric Boersma, Ph. Gabriel Steg, Frank van Leeuwen, Christoph Bode, John P Greenwood, Tessa Rademaker-Havinga, William Wijns, Peter W. Radke, Edoardo Camenzind
Publikováno v:
European Heart Journal, 35(40), 2812-2820. Oxford University Press
Aims To compare the long-term clinical safety between two drug-eluting stents with different healing characteristics in the Patient Related Outcomes with Endeavour (E-ZES) vs. Cypher (C-SES) Stenting Trial (PROTECT). At 3 years, there was no differen
Autor:
Sandeep Brar, Stephan Windecker, Jorge Belardi, Ajay J. Kirtane, Martin T. Rothman, Sigmund Silber, Minglei Liu
Publikováno v:
Silber, Sigmund; Kirtane, Ajay J; Belardi, Jorge A; Liu, Minglei; Brar, Sandeep; Rothman, Martin; Windecker, Stephan (2014). Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation. European Heart Journal, 35(29), pp. 1949-1956. Oxford University Press 10.1093/eurheartj/ehu026
Aim The optimal duration of dual antiplatelet therapy (DAPT) following the use of new generation drug-eluting stents is unknown. Methods and results The association between DAPT interruption and the rates of stent thrombosis (ST) and cardiac death/ta
Autor:
Barry H. Greenberg, Elaine Unemori, Gad Cotter, Thomas Severin, Tsushung Hua, Marco Metra, Gerasimos Filippatos, John R. Teerlink, Beth A. Davison, Adriaan A. Voors, G. Michael Felker, Dimitrios Farmakis, Piotr Ponikowski
Publikováno v:
European Heart Journal
European Heart Journal, 35(16), 1041-1050. Oxford University Press
European Heart Journal, 35(16), 1041-1050. Oxford University Press
Aims Serelaxin is effective in relieving dyspnoea and improving multiple outcomes in acute heart failure (AHF). Many AHF patients have preserved ejection fraction (HFpEF). Given the lack of evidence-based therapies in this population, we evaluated th
Autor:
Thomas J, Povsic, John P, Vavalle, Laura H, Aberle, Jaroslaw D, Kasprzak, Mauricio G, Cohen, Roxana, Mehran, Christoph, Bode, Christopher E, Buller, Gilles, Montalescot, Jan H, Cornel, Andrzej, Rynkiewicz, Michael E, Ring, Uwe, Zeymer, Madhu, Natarajan, Nicolas, Delarche, Steven L, Zelenkofske, Richard C, Becker, John H, Alexander, Rebecca, Torguson
Publikováno v:
European Heart Journal. 34:2481-2489
Aims We sought to determine the degree of anticoagulation reversal required to mitigate bleeding, and assess the feasibility of using pegnivacogin to prevent ischaemic events in acute coronary syndrome (ACS) patients managed with an early invasive ap
Autor:
Hélène Petit-Eisenmann, Pascal Gueret, Damien Metz, Christophe Tribouilloy, Agnes Pasquet, Serge Baleynaud, Jean-Luc Monin, Mehran Monchi, Christophe Chauvel, Emilie Fougeres, Dan Rusinaru, Catherine Adams
Publikováno v:
European Heart Journal. 33:2426-2433
In the setting of low-flow/low-gradient aortic stenosis (LF/LGAS), outcomes of pseudo-severe aortic stenosis (AS) remain poorly described. This study was aimed to assess the outcome of patients with pseudo-severe AS under conservative treatment.Among